Perfluorohexyloctane

From Wikipedia, the free encyclopedia

Perfluorohexyloctane
Clinical data
Trade namesMiebo
Other namesNOV03; 1-(perfluorohexyl)octane
AHFS/Drugs.comMonograph
MedlinePlusa623054
License data
Routes of
administration		Eye drops
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H17F13
Molar mass432.269 g·mol−1
3D model (JSmol)
  • CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
  • InChI=1S/C14H17F13/c1-2-3-4-5-6-7-8-9(15,16)10(17,18)11(19,20)12(21,22)13(23,24)14(25,26)27/h2-8H2,1H3
  • Key:WRYIIOKOQSICTB-UHFFFAOYSA-N

Perfluorohexyloctane, sold under the brand names EvoTears[2] (Europe), NovaTears[3] (Australia, New Zealand), and Miebo (USA), is a medication used for the treatment of dry eye disease.[1] It is a semifluorinated alkane.[1]

Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names EvoTears and NovaTears,[4] and was additionally approved for medical use in the United States in May 2023 under the brand Miebo.[1][5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6]

Perfluorohexyloctane when sold under the brand names EvoTears or NovaTears is available in multiple countries over-the-counter[7] costing NZ$34.00,[8] AUD: $30,[9] €30[10] for approximately a one-month supply. When sold in the USA under the brand Miebo a prescription is required.

Medical uses[edit]

Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease.[1][11][12]

References[edit]

  1. ^ a b c d e "Miebo- perfluorohexyloctane solution". DailyMed. 18 May 2023. Retrieved 8 June 2023.
  2. ^ "EvoTears - Official Website". Retrieved 15 February 2024.
  3. ^ "NovaTears - AFT Pharmaceuticals". Retrieved 15 February 2024.
  4. ^ "URSAPHARM GmbH and Novaliq GmbH Announce European Partnership Agreement". Retrieved 15 February 2024.
  5. ^ "Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease" (Press release). Bausch + Lomb Corporation. 18 May 2023. Retrieved 8 June 2023 – via Business Wire.
  6. ^ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.
  7. ^ "Global Availability Announcement". Retrieved 15 February 2024.
  8. ^ "Novatears 3ml - Life Pharmacy New Zealand". Retrieved 15 February 2024.
  9. ^ "NovaTears Preservative Free Lubricating Eye Drops 3ml - Chemist Warehouse Australia". Retrieved 15 February 2024.
  10. ^ "Evotears Eye Drops 3ml - Amazon.de". Retrieved 15 February 2024.
  11. ^ Ballesteros-Sánchez A, De-Hita-Cantalejo C, Sánchez-González MC, Jansone-Langine Z, de Sotomayor MA, Culig J, et al. (October 2023). "Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent". The Ocular Surface. 30: 254–262. doi:10.1016/j.jtos.2023.10.001. hdl:11441/151762. PMID 37813152. S2CID 263802332.
  12. ^ Sheppard JD, Evans DG, Protzko EE (November 2023). "A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution". The American Journal of Managed Care. 29 (14 Suppl): S251–S259. doi:10.37765/ajmc.2023.89464. PMID 37930231. S2CID 265032840.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Perfluorohexyloctane&oldid=1209336447"